Skip to content
Company Analysis

Haleon plc HLN

A comprehensive view of key metrics, scores, and financial health for Haleon plc

Overview of Haleon plc

HLN NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Large Cap
Haleon plc (HLN), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $9.13, about 37.9% overvalued vs fair value, -16.0% 1Y return, placing in the top 10% of its sector.
USD 9.13
1.11%
(Delayed)
• Vol 90d: 24.8%
52-Week Range
Market Cap
$39.48B
Enterprise Value
$47.26B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Fair
Valuation
Good
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Fair
Valuation
Good
Completeness: 82%
Confidence: 88%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.haleon.com
HQ Weybridge
Employees 24,561
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$5
$6
$6
Current: $9.13 -38% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$11.2B
-0.6%%
Gross Profit
$6.8B
1.1%%
R&D Expense
$298.0M
-4.2%%
Operating Income (EBIT)
$2.3B
12.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
99.9%
Good

Good cash conversion

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$1.2B
60.0% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
0/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Haleon plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
67
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
75
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 93% Coverage
Trade-Off Triangle Visualization A ternary plot showing HLN's balance between Growth (27.3%), Profitability (40.1%), and Safety (32.5%). Growth 27% Safety 33% Profitability 40%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

47th percentile vs peers
47
Key Signals
Revenue CAGR 3Y 5.6% 53p EPS Growth YoY 38.9% 54p Rev Growth YoY -0.6% 31p EPS CAGR 3Y 1.4% 59p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Debt/FCF Ratio in top 20% of peers (5.09, 80th percentile)
  • Consistently strong margins across 6 metrics
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

69th percentile vs peers
70
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

56th percentile vs peers
57
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Haleon plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$5.67
- - -
-37.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000